Road to 2025: RCE
Sarah Hughan explores Recce Pharmaceuticals and a series of successes advancing a new class of synthetic anti-infectives.
Stockhead
Morgans’ ASX health picks for 2025
Morgans healthcare and life sciences experts Iain Wilkie and Scott Power give Stockhead readers their top picks for 2025.
Bell Potter’s top tech and health stocks for 2025
Australian stockbroking and financial advisory firm Bell Potter is bullish on these tech stocks and healthcare stocks for 2025.
No Christmas break for Legacy in its tier one quest
Junior explorer Legacy Minerals believes its large landholding and tier one partners position it as having a strong chance of making a major discovery.
More Stories
How gas policy is letting Australia down
Australia needs more gas to offset declining supplies from ageing fields but government policy appears to getting in the way of achieving this goal.
GOT GAS: Kipper easing gas woes? Think again
The start-up of the Kipper Compression Project will keep gas flowing from the Kipper field but its impact on East Coast supplies has already been accounted for.
LTR Pharma inks deal with men’s health provider
LTR Pharma has signed an access agreement with Mens Health Downunder to facilitate supply of Spontan, its novel nasal spray treatment for erectile dysfunction.
BlinkLab’s autism product gets global check
Stockhead TV’s Sarah Hughan brings you today’s Break it Down, detailing the positive outcome from the US Food and Drug Administration from BlinkLab.
BlinkLab gains FDA support for trial
BlinkLab has received a positive outcome from a pre-submission meeting with the FDA on a regulatory pathway for its BlinkLab Dx 1 platform as an autism diagnosis aid.
Road to 2025: PRX
Sarah Hughan delves into Prodigy Gold and its advancement towards shovel-ready in its proven, yet underexplored end of the Tanami.
Neurizon gains EU orphan status for motor neurone drug
European Medicines Agency grants orphan drug designation for Neurizon’s lead drug candidate NUZ-001 to treat Amyotrophic Lateral Sclerosis.
Fed triggers Wall Street (and ASX) sell-off
The ASX plunged nearly 2pc earlier, as a brutal Wall Street sell-off followed the Fed’s cautious outlook, signalling just two rate cuts for 2025.
Adisyn wraps up due diligence on 2DG
Adisyn’s acquisition of 2DG could help capture opportunities in the hot and emerging semiconductor market.
Guy on Rocks: MNB
Guy Le Page looks into Minbos Resources and a phosphate opportunity to build a breadbasket in a nation which imports all of its fertiliser.
Original URL: https://www.adelaidenow.com.au/business/stockhead/page/6